|
23 Companies |
|
30 Products |
|
30 Products |
|
0 Mechanisms of Action |
|
0 Trials |
|
425 News |
|
| «123456789» |
- Trial completion, Enrollment change: BEET-PAH: BEET PAH: a Study to Assess the Effects of Beetroot Juice in Patients With Pulmonary Arterial Hypertension (clinicaltrials.gov) - Dec 6, 2015
P=N/A, N=15, Completed, Sponsor: Uppsala University
Recruiting --> Completed | N=20 --> 15
- Enrollment change, Trial withdrawal: Evaluating Pulmonary Arterial Hypertension in Patients With Systemic Sclerosis (clinicaltrials.gov) - Dec 4, 2015
P=N/A, N=0, Withdrawn, Sponsor: Echosense Ltd.
Recruiting --> Completed | N=20 --> 15 N=20 --> 0 | Not yet recruiting --> Withdrawn
- Enrollment change, Trial withdrawal: Evaluation of Pulmonary Doppler Signals in Patients With Systemic Sclerosis(SSc) (clinicaltrials.gov) - Dec 4, 2015
P=N/A, N=0, Withdrawn, Sponsor: Echosense Ltd.
N=20 --> 0 | Not yet recruiting --> Withdrawn N=20 --> 0 | Recruiting --> Withdrawn
- Enrollment change, Trial termination: Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc) (clinicaltrials.gov) - Dec 4, 2015
P=N/A, N=5, Terminated, Sponsor: Echosense Ltd.
N=20 --> 0 | Recruiting --> Withdrawn N=20 --> 5 | Recruiting --> Terminated; Low recruitment rate
- Enrollment change, Trial termination: Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc) by Ultrasound (clinicaltrials.gov) - Dec 4, 2015
P=N/A, N=1, Terminated, Sponsor: Echosense Ltd.
N=20 --> 5 | Recruiting --> Terminated; Low recruitment rate N=20 --> 1 | Not yet recruiting --> Terminated; Low recruitment rate
- || Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Enrollment closed, Trial primary completion date: SPHERA: Efficacy of Ventavis Used in Real-life Setting. (clinicaltrials.gov) - Nov 28, 2015
P=N/A, N=60, Active, not recruiting, Sponsor: Bayer
N=20 --> 1 | Not yet recruiting --> Terminated; Low recruitment rate Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> Apr 2016
- Biomarker, Enrollment open, Trial primary completion date: The Screening and Analysis of Plasma Biomarkers in Irreversible PAH-CHD (clinicaltrials.gov) - Nov 24, 2015
P=N/A, N=100, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> Apr 2016 Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2015 --> Sep 2016
- treprostinil / Generic mfg.
Trial primary completion date: PKRemodulin: Pharmacokinetic Study of Sub-q and IV Treprostinil in Kids With Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Nov 21, 2015
P=N/A, N=50, Recruiting, Sponsor: Jeffrey A. Feinstein
Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2015 --> Sep 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- carvedilol / Generic mfg.
Trial suspension, Trial primary completion date: Beta Blockers for Treatment of Pulmonary Arterial Hypertension in Children (clinicaltrials.gov) - Nov 17, 2015
P1/2, N=10, Suspended, Sponsor: The Hospital for Sick Children
Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Suspended | Trial primary completion date: Sep 2016 --> Sep 2015
- ||||| Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment closed: RESPITE: Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor (clinicaltrials.gov) - Nov 11, 2015
P3, N=60, Active, not recruiting, Sponsor: Bayer
Recruiting --> Suspended | Trial primary completion date: Sep 2016 --> Sep 2015 Recruiting --> Active, not recruiting
- ||| tadalafil / Generic mfg.
Trial completion, Enrollment change: Post Marketing Observational Study in Patients With Pulmonary Arterial Hypertension (clinicaltrials.gov) - Oct 27, 2015
P=N/A, N=1809, Completed, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=1165 --> 1809
- Trial primary completion date, FDG PET: Look at Way the Heart Functions in People With Pulmonary Hypertension (PH) Who Have Near Normal Right Ventricle (RV) Function and People With Pulmonary Hypertension Who Have Impaired RV Function. Using Imaging Studies PET Scan and Cardiac MRI. (clinicaltrials.gov) - Oct 23, 2015
P2, N=36, Recruiting, Sponsor: Brigham and Women's Hospital
Active, not recruiting --> Completed | N=1165 --> 1809 Trial primary completion date: Jun 2015 --> Jun 2016
- ||| selonsertib (GS-4997) / Gilead
Enrollment closed: ARROW: Selonsertib in Adults With Pulmonary Arterial Hypertension (clinicaltrials.gov) - Oct 22, 2015
P2, N=120, Active, not recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Jun 2015 --> Jun 2016 Recruiting --> Active, not recruiting
- || Enrollment closed: Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients (clinicaltrials.gov) - Sep 25, 2015
P=N/A, N=400, Active, not recruiting, Sponsor: Georgetown University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- emiplacel (PLX-PAD) - Pluristem, Charite / University of Medicine Berlin
PK/PD data, Trial primary completion date: Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Sep 24, 2015
P1, N=9, Recruiting, Sponsor: United Therapeutics
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> Aug 2016
- ||||| Zydena (udenafil) / Mezzion
Enrollment closed: Clinical Trial to Evaluate the Long-term Safety of Udenafil in Patient With PAH (clinicaltrials.gov) - Sep 16, 2015
P2/3, N=59, Active, not recruiting, Sponsor: Dong-A ST Co., Ltd.
Trial primary completion date: Dec 2015 --> Aug 2016 Recruiting --> Active, not recruiting
- Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial primary completion date, Compliance: Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation (clinicaltrials.gov) - Aug 22, 2015
P=N/A, N=15, Recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2016 --> Dec 2016
- ||| Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment change: Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION) (clinicaltrials.gov) - Aug 22, 2015
P4, N=100, Recruiting, Sponsor: Bayer
Trial primary completion date: Jan 2016 --> Dec 2016 N=61 --> 100
- || Trial primary completion date: PHiano: Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl. (clinicaltrials.gov) - Aug 14, 2015
P2, N=75, Recruiting, Sponsor: Geno LLC
N=61 --> 100 Trial primary completion date: May 2013 --> May 2016
- || tadalafil / Generic mfg.
Enrollment closed: Post Marketing Observational Study in Patients With Pulmonary Arterial Hypertension (clinicaltrials.gov) - Aug 13, 2015
P=N/A, N=1165, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: May 2013 --> May 2016 Completed --> Active, not recruiting
- ||| Trial completion, Trial primary completion date, Surgery: Symptomatic Pulmonary Arterial Hypertension After Mitral Valve Surgery (clinicaltrials.gov) - Aug 12, 2015
P=N/A, N=100, Completed, Sponsor: Duke University
Completed --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Dec 2014
- Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Enrollment closed, Enrollment change, Compliance: Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients (clinicaltrials.gov) - Aug 12, 2015
P=N/A, N=17, Active, not recruiting, Sponsor: Bayer
Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Dec 2014 Recruiting --> Active, not recruiting | N=30 --> 17
- | Trial completion, Enrollment change: Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005) (clinicaltrials.gov) - Aug 11, 2015
P1, N=23, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting | N=30 --> 17 Terminated --> Completed | N=18 --> 23
- Thelin (oral sitaxsentan) / Pfizer, Tracleer (bosentan) / J&J, Roche
Trial completion, Trial primary completion date: Role of Endothelin-A (ETA) and Endothelin-B (ETB) Receptors in the Vasodilatory Response to Endothelin-3 (ET-3) (clinicaltrials.gov) - Jul 21, 2015
P0, N=10, Completed, Sponsor: University of Edinburgh
Terminated --> Completed | N=18 --> 23 Active, not recruiting --> Completed | Trial primary completion date: Sep 2010 --> Sep 2009
- imatinib / Generic mfg.
Trial termination: Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Jul 13, 2015
P3, N=17, Terminated, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Sep 2010 --> Sep 2009 Completed --> Terminated; Novartis discontinued the development of imatinib in PAH due to requirement of regulatory authorities for additional data to secure marketing approval in PAH.
- Enrollment open, Trial primary completion date: Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension (clinicaltrials.gov) - Jun 24, 2015
P2, N=11, Recruiting, Sponsor: American Medical Association Foundation
Completed --> Terminated; Novartis discontinued the development of imatinib in PAH due to requirement of regulatory authorities for additional data to secure marketing approval in PAH. Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2014 --> Jul 2016
- |||| Zydena (udenafil) / Mezzion
Trial completion, Enrollment change, Trial primary completion date: Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH) (clinicaltrials.gov) - Jun 18, 2015
P2, N=63, Completed, Sponsor: Dong-A ST Co., Ltd.
Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2014 --> Jul 2016 Recruiting --> Completed | N=18 --> 63 | Trial primary completion date: Aug 2013 --> Mar 2015
- carvedilol / Generic mfg.
Trial primary completion date: Beta Blockers for Treatment of Pulmonary Arterial Hypertension in Children (clinicaltrials.gov) - Jun 16, 2015
P1/2, N=10, Recruiting, Sponsor: The Hospital for Sick Children
Recruiting --> Completed | N=18 --> 63 | Trial primary completion date: Aug 2013 --> Mar 2015 Trial primary completion date: Sep 2014 --> Sep 2016
- ranolazine ER / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension (clinicaltrials.gov) - Jun 12, 2015
P1, N=12, Completed, Sponsor: University of Chicago
Trial primary completion date: Sep 2014 --> Sep 2016 Active, not recruiting --> Completed | N=16 --> 12 | Trial primary completion date: Dec 2015 --> Jan 2015
- Tyvaso (treprostinil) / United Therapeutics Corp
Trial primary completion date: Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication (clinicaltrials.gov) - Jun 11, 2015
P4, N=21, Active, not recruiting, Sponsor: Los Angeles Biomedical Research Institute
Active, not recruiting --> Completed | N=16 --> 12 | Trial primary completion date: Dec 2015 --> Jan 2015 Trial primary completion date: Dec 2014 --> Dec 2015
- Opsumit (macitentan) / Nippon Shinyaku, J&J
Enrollment closed, Trial primary completion date: SYMPHONYext: Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT Instrument (clinicaltrials.gov) - May 19, 2015
P3, N=4, Active, not recruiting, Sponsor: Actelion
Trial primary completion date: Dec 2014 --> Dec 2015 Completed --> Active, not recruiting | Trial primary completion date: Jan 2014 --> May 2016
- ||||| Opsumit (macitentan) / Nippon Shinyaku, J&J
Enrollment closed, Trial primary completion date: Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument (clinicaltrials.gov) - May 16, 2015
P3, N=275, Active, not recruiting, Sponsor: Actelion
Completed --> Active, not recruiting | Trial primary completion date: Jan 2014 --> May 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Sep 2015
- Enrollment closed, Trial primary completion date, IO biomarker: Auto-HTAP: Auto-immunity and Pulmonary Arterial Hypertension (clinicaltrials.gov) - Apr 30, 2015
P=N/A, N=629, Active, not recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Sep 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Sep 2015
- ||| Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment change: Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION) (clinicaltrials.gov) - Apr 28, 2015
P4, N=61, Recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Sep 2015 N=100 --> 61
- anastrozole / Generic mfg.
Enrollment closed, Trial primary completion date: Anastrozole in Patients With Pulmonary Arterial Hypertension (clinicaltrials.gov) - Apr 23, 2015
P2, N=18, Active, not recruiting, Sponsor: University of Pennsylvania
N=100 --> 61 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> Jun 2015
- |||| Opsumit (macitentan) / Nippon Shinyaku, J&J
Trial primary completion date: A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and Spain (clinicaltrials.gov) - Apr 21, 2015
P3, N=160, Recruiting, Sponsor: Actelion
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> Jun 2015 Trial primary completion date: Dec 2014 --> Jul 2015
- | epoprostenol intravenous / Generic mfg.
Trial primary completion date: Epoprostenol for Injection in Patients With Pulmonary Arterial Hypertension (clinicaltrials.gov) - Apr 15, 2015
P3, N=41, Active, not recruiting, Sponsor: Actelion
Trial primary completion date: Dec 2014 --> Jul 2015 Trial primary completion date: Mar 2014 --> Jun 2015
- Trial primary completion date, Heterogeneity, Compliance: Evaluation of Pulmonary Perfusion Heterogeneity and Compliance in Patients With Pulmonary Hypertension Using Positron Emission Tomography Imaging (clinicaltrials.gov) - Apr 15, 2015
P=N/A, N=15, Recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Mar 2014 --> Jun 2015 Trial primary completion date: Jul 2014 --> Jul 2016
- Enrollment closed, Enrollment change, Trial primary completion date: Carbon Monoxide Therapy for Severe Pulmonary Arterial Hypertension (clinicaltrials.gov) - Apr 3, 2015
P1/2, N=3, Active, not recruiting, Sponsor: University of Illinois at Chicago
Trial primary completion date: Jul 2014 --> Jul 2016 Not yet recruiting --> Active, not recruiting | N=20 --> 3 | Trial primary completion date: Dec 2014 --> Dec 2015
- ||| Tyvaso (treprostinil) / United Therapeutics Corp
Trial completion, Real-world evidence, Real-world: Tyvaso Dosing and Titration Evaluation: TyTRATE Registry (clinicaltrials.gov) - Mar 24, 2015
P=N/A, N=98, Completed, Sponsor: United Therapeutics
Not yet recruiting --> Active, not recruiting | N=20 --> 3 | Trial primary completion date: Dec 2014 --> Dec 2015 Active, not recruiting --> Completed
- | Orenitram (treprostinil diethanolamine oral) / United Therapeutics Corp
Trial completion: Remodulin (clinicaltrials.gov) - Mar 24, 2015
P2, N=33, Completed, Sponsor: United Therapeutics
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Phase III Randomized Study of UT-15 in Patients With Primary Pulmonary Hypertension (clinicaltrials.gov) - Mar 23, 2015
P3, N=0, Completed, Sponsor: United Therapeutics
Active, not recruiting --> Completed Recruiting --> Completed
- | Trial completion: Coenzyme Q-10 and Pulmonary Arterial Hypertension (clinicaltrials.gov) - Mar 20, 2015
P=N/A, N=18, Completed, Sponsor: The Cleveland Clinic
Recruiting --> Completed Active, not recruiting --> Completed
- ranolazine ER / Generic mfg.
Enrollment closed, Trial primary completion date: A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension (clinicaltrials.gov) - Mar 11, 2015
P1, N=16, Active, not recruiting, Sponsor: University of Chicago
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Dec 2015
- Thelin (oral sitaxsentan) / Pfizer
Enrollment change: Drug Interaction Between Ritonavir And Sitaxsentan (clinicaltrials.gov) - Mar 7, 2015
P1, N=0, Withdrawn, Sponsor: Pfizer
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Dec 2015 N=18 --> 0
- Thelin (oral sitaxsentan) / Pfizer
Enrollment change: Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan (clinicaltrials.gov) - Mar 7, 2015
P1, N=0, Withdrawn, Sponsor: Pfizer
N=18 --> 0 N=16 --> 0
- ||||||| Uptravi (selexipag) / J&J, Nippon Shinyaku
Trial completion: GRIPHON: Selexipag (ACT-293987) in Pulmonary Arterial Hypertension (clinicaltrials.gov) - Feb 27, 2015
P3, N=1156, Completed, Sponsor: Actelion
N=16 --> 0 Active, not recruiting --> Completed
- emiplacel (PLX-PAD) - Pluristem, Charite / University of Medicine Berlin
PK/PD data, Trial primary completion date: Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Feb 20, 2015
P1, N=9, Recruiting, Sponsor: United Therapeutics
Active, not recruiting --> Completed Trial primary completion date: Mar 2015 --> Dec 2015
- ||| tadalafil / Generic mfg.
Trial completion: Post Marketing Observational Study in Patients With Pulmonary Arterial Hypertension (clinicaltrials.gov) - Feb 19, 2015
P=N/A, N=1165, Completed, Sponsor: Eli Lilly and Company
Trial primary completion date: Mar 2015 --> Dec 2015 Active, not recruiting --> Completed
- ||| Tyvaso (treprostinil) / United Therapeutics Corp
Trial completion, Adverse events: Aspire: Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso (clinicaltrials.gov) - Feb 19, 2015
P=N/A, N=1320, Completed, Sponsor: United Therapeutics
Active, not recruiting --> Completed Active, not recruiting --> Completed